These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

735 related articles for article (PubMed ID: 31792461)

  • 41. Targeting antioxidant enzymes enhances the therapeutic efficacy of the BCL-X
    Oh Y; Jung HR; Min S; Kang J; Jang D; Shin S; Kim J; Lee SE; Sung CO; Lee WS; Lee C; Jeong EM; Cho SY
    Cancer Lett; 2021 Jan; 497():123-136. PubMed ID: 33068701
    [TBL] [Abstract][Full Text] [Related]  

  • 42. A novel therapeutic combination sequentially targeting aurora B and Bcl-xL in hepatocellular carcinoma.
    Matsunaga H; Tanaka S; Aihara A; Ogawa K; Matsumura S; Ban D; Ochiai T; Irie T; Kudo A; Nakamura N; Arii S; Tanabe M
    Ann Surg Oncol; 2015 Sep; 22(9):3079-86. PubMed ID: 25524010
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Reversal of Mutant KRAS-Mediated Apoptosis Resistance by Concurrent Noxa/Bik Induction and Bcl-2/Bcl-xL Antagonism in Colon Cancer Cells.
    Okamoto K; Zaanan A; Kawakami H; Huang S; Sinicrope FA
    Mol Cancer Res; 2015 Apr; 13(4):659-69. PubMed ID: 25548100
    [TBL] [Abstract][Full Text] [Related]  

  • 44. PROTACs are effective in addressing the platelet toxicity associated with BCL-X
    Zhang P; Zhang X; Liu X; Khan S; Zhou D; Zheng G
    Explor Target Antitumor Ther; 2020; 1(4):259-272. PubMed ID: 34296214
    [TBL] [Abstract][Full Text] [Related]  

  • 45. A small-molecule inhibitor of Bcl-XL potentiates the activity of cytotoxic drugs in vitro and in vivo.
    Shoemaker AR; Oleksijew A; Bauch J; Belli BA; Borre T; Bruncko M; Deckwirth T; Frost DJ; Jarvis K; Joseph MK; Marsh K; McClellan W; Nellans H; Ng S; Nimmer P; O'Connor JM; Oltersdorf T; Qing W; Shen W; Stavropoulos J; Tahir SK; Wang B; Warner R; Zhang H; Fesik SW; Rosenberg SH; Elmore SW
    Cancer Res; 2006 Sep; 66(17):8731-9. PubMed ID: 16951189
    [TBL] [Abstract][Full Text] [Related]  

  • 46. BH3-mimetics and BET-inhibitors elicit enhanced lethality in malignant glioma.
    Ishida CT; Bianchetti E; Shu C; Halatsch ME; Westhoff MA; Karpel-Massler G; Siegelin MD
    Oncotarget; 2017 May; 8(18):29558-29573. PubMed ID: 28418907
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Elimination of quiescent/slow-proliferating cancer stem cells by Bcl-XL inhibition in non-small cell lung cancer.
    Zeuner A; Francescangeli F; Contavalli P; Zapparelli G; Apuzzo T; Eramo A; Baiocchi M; De Angelis ML; Biffoni M; Sette G; Todaro M; Stassi G; De Maria R
    Cell Death Differ; 2014 Dec; 21(12):1877-88. PubMed ID: 25034785
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Heterogeneous Pattern of Dependence on Anti-Apoptotic BCL-2 Family Proteins upon CHOP Treatment in Diffuse Large B-Cell Lymphoma.
    de Jong MRW; Langendonk M; Reitsma B; Nijland M; van den Berg A; Ammatuna E; Visser L; van Meerten T
    Int J Mol Sci; 2019 Nov; 20(23):. PubMed ID: 31801186
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Discovery of potent Mcl-1/Bcl-xL dual inhibitors by using a hybridization strategy based on structural analysis of target proteins.
    Tanaka Y; Aikawa K; Nishida G; Homma M; Sogabe S; Igaki S; Hayano Y; Sameshima T; Miyahisa I; Kawamoto T; Tawada M; Imai Y; Inazuka M; Cho N; Imaeda Y; Ishikawa T
    J Med Chem; 2013 Dec; 56(23):9635-45. PubMed ID: 24215352
    [TBL] [Abstract][Full Text] [Related]  

  • 50. A novel Bcl-2 inhibitor, BM-1197, induces apoptosis in malignant lymphoma cells through the endogenous apoptotic pathway.
    Sun YL; Jiang WQ; Luo QY; Yang DJ; Cai YC; Huang HQ; Sun J
    BMC Cancer; 2019 Dec; 20(1):1. PubMed ID: 31892356
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Clearance of senescent cells by ABT263 rejuvenates aged hematopoietic stem cells in mice.
    Chang J; Wang Y; Shao L; Laberge RM; Demaria M; Campisi J; Janakiraman K; Sharpless NE; Ding S; Feng W; Luo Y; Wang X; Aykin-Burns N; Krager K; Ponnappan U; Hauer-Jensen M; Meng A; Zhou D
    Nat Med; 2016 Jan; 22(1):78-83. PubMed ID: 26657143
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Bcl-xL-inhibitory BH3 mimetics can induce a transient thrombocytopathy that undermines the hemostatic function of platelets.
    Schoenwaelder SM; Jarman KE; Gardiner EE; Hua M; Qiao J; White MJ; Josefsson EC; Alwis I; Ono A; Willcox A; Andrews RK; Mason KD; Salem HH; Huang DC; Kile BT; Roberts AW; Jackson SP
    Blood; 2011 Aug; 118(6):1663-74. PubMed ID: 21673344
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Bcl-xL-inhibitory BH3 mimetic ABT-737 depletes platelet calcium stores.
    Harper MT; Poole AW
    Blood; 2012 May; 119(18):4337-8. PubMed ID: 22555663
    [No Abstract]   [Full Text] [Related]  

  • 54. MCL1 and BCL-xL levels in solid tumors are predictive of dinaciclib-induced apoptosis.
    Booher RN; Hatch H; Dolinski BM; Nguyen T; Harmonay L; Al-Assaad AS; Ayers M; Nebozhyn M; Loboda A; Hirsch HA; Zhang T; Shi B; Merkel CE; Angagaw MH; Wang Y; Long BJ; Lennon XQ; Miselis N; Pucci V; Monahan JW; Lee J; Kondic AG; Im EK; Mauro D; Blanchard R; Gilliland G; Fawell SE; Zawel L; Schuller AG; Strack P
    PLoS One; 2014; 9(10):e108371. PubMed ID: 25289887
    [TBL] [Abstract][Full Text] [Related]  

  • 55. BCLXL PROTAC degrader DT2216 targets secondary plasma cell leukemia addicted to BCLXL for survival.
    Champion O; Soler A; Maïga S; Bellanger C; Pellat-Deceunynck C; Talbot A; Touzeau C; Amiot M; Gomez-Bougie P
    Front Oncol; 2023; 13():1196005. PubMed ID: 37534243
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Navitoclax (ABT-263) accelerates apoptosis during drug-induced mitotic arrest by antagonizing Bcl-xL.
    Shi J; Zhou Y; Huang HC; Mitchison TJ
    Cancer Res; 2011 Jul; 71(13):4518-26. PubMed ID: 21546570
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Inhibition of Bcl-xL by ABT-737 enhances chemotherapy sensitivity in neurofibromatosis type 1-associated malignant peripheral nerve sheath tumor cells.
    Lee SJ; Park HJ; Kim YH; Kim BY; Jin HS; Kim HJ; Han JH; Yim H; Jeong SY
    Int J Mol Med; 2012 Aug; 30(2):443-50. PubMed ID: 22664653
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Studies leading to potent, dual inhibitors of Bcl-2 and Bcl-xL.
    Bruncko M; Oost TK; Belli BA; Ding H; Joseph MK; Kunzer A; Martineau D; McClellan WJ; Mitten M; Ng SC; Nimmer PM; Oltersdorf T; Park CM; Petros AM; Shoemaker AR; Song X; Wang X; Wendt MD; Zhang H; Fesik SW; Rosenberg SH; Elmore SW
    J Med Chem; 2007 Feb; 50(4):641-62. PubMed ID: 17256834
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Combined inhibition of RAC1 and Bcl-2/Bcl-xL synergistically induces glioblastoma cell death through down-regulation of the Usp9X/Mcl-1 axis.
    Hlavac M; Dwucet A; Kast RE; Engelke J; Westhoff MA; Siegelin MD; Debatin KM; Wirtz CR; Halatsch ME; Karpel-Massler G
    Cell Oncol (Dordr); 2019 Jun; 42(3):287-301. PubMed ID: 30859392
    [TBL] [Abstract][Full Text] [Related]  

  • 60. BCL-X
    Judd AS; Bawa B; Buck WR; Tao ZF; Li Y; Mitten MJ; Bruncko M; Catron N; Doherty G; Durbin KR; Enright B; Frey R; Haasch D; Haman S; Haight AR; Henriques TA; Holms J; Izeradjene K; Judge RA; Jenkins GJ; Kunzer A; Leverson JD; Martin RL; Mitra D; Mittelstadt S; Nelson L; Nimmer P; Palma J; Peterson R; Phillips DC; Ralston SL; Rosenberg SH; Shen X; Song X; Vaidya KS; Wang X; Wang J; Xiao Y; Zhang H; Zhang X; Blomme EA; Boghaert ER; Kalvass JC; Phillips A; Souers AJ
    Sci Adv; 2024 Oct; 10(40):eado7120. PubMed ID: 39365864
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 37.